Hematologic Malignancies Program

Ask the Expert

Get answers to questions about Myelodysplastic Syndromes by e-mailing Dr. Maria Baer.

Note: This is for informational purposes only. Doctors cannot provide a diagnosis via e-mail.

Our Program for Hematologic Malignancies is built on a long-standing tradition of excellence. From its inception as an extramural program of the National Cancer Institute, The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been at the forefront of developing and testing new therapies for hematologic malignancies.

As one of the biggest experimental therapeutics programs on the East Coast, we offer experimental therapies for all stages of leukemia, lymphoma, Hodgkin's disease and multiple myeloma.

Our team of experts includes internationally and nationally recognized leaders in this field, and we continue to set the standard for treating patients with:

MDS Foundation Center of Excellence

UMGCC has been named a Center of Excellence by the Myelodysplastic Syndromes Foundation.

Acute and chronic leukemia
Lymphomas, including Hodgkin's disease
Multiple myeloma and other similar disease disorders
AIDS-related lymphomas

Working with referring physicians to provide patients with the best possible care, we treat all types of hematologic malignancies. Our experts work together throughout the treatment process to ensure that patients receive the highly individualized program of care they need while undergoing complex, aggressive therapies.

UM Experts Present Findings at American Society of Hematology Annual Meeting
Video: Understanding Leukemia and Lymphoma: Interview with Maria Baer, M.D.
Read a Q&A with Maria Baer, M.D., head of Hematologic Malignancies at UMGCC
UMGCC Named a Center of Excellence by the Myelodysplastic Syndromes Foundation

This page was last updated on: July 25, 2008.